Bayer sells oncology asset Stivarga for €375m
German global life science and pharmaceutical company Bayer has divested its established oncology asset Stivarga to the German pharmaceutical firm Grünenthal for a total consideration of up to €375m. The transaction, announced in September 2026, involves the transfer of rights for Stivarga, also known as regorafenib, which is a once daily oral multikinase inhibitor approved in more than 90 markets…